Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 232

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome

Open access
Derks, Jules L., Leblay, Noémie, Thunnissen, Erik, van Suylen, Robert Jan, den Bakker, Michael, Groen, Harry J.M., Smit, Egbert F., Damhuis, Ronald, van den Broek, Esther C., Charbrier, Amélie, Foll, Matthieu, McKay, James D., Fernandez-Cuesta, Lynnette, Speel, Ernst-Jan M., Dingemans, Anne-Marie C. · 2018 · Clinical Cancer Research

Abstract

Purpose: Previous genomic studies have identified two mutually exclusive molecular subtypes of large-cell neuroendocrine carcinoma (LCNEC): the RB1 mutated (mostly comutated with TP53) and the RB1 wild-type groups. We assessed whether these subtypes have a predictive value on chemotherapy outcome. Experimental Design: Clinical data and tumor specimens were retrospectively obtained from the Netherlands Cancer Registry and Pathology Registry. Panel-consensus pathology revision confirmed the diagnosis of LCNEC in 148 of 232 cases. Next-generation sequencing (NGS) for TP53, RB1, STK11, and KEAP1 genes, as well as IHC for RB1 and P16 was performed on 79 and 109 cases, respectively, and correlated with overall survival (OS) and progression-free survival (PFS), stratifying for non–small cell lung cancer type chemotherapy including platinum + gemcitabine or taxanes (NSCLC-GEM/TAX) and platinum-etoposide (SCLC-PE). Results: RB1 mutation and protein loss were detected in 47% (n = 37) and 72% (n = 78) of the cases, respectively. Patients with RB1 wild-type LCNEC treated with NSCLC-GEM/TAX had a significantly longer OS [9.6; 95% confidence interval (CI), 7.7–11.6 months] than those treated with SCLC-PE [5.8 (5.5–6.1); P = 0.026]. Similar results were obtained for patients expressing RB1 in their tumors (P = 0.001). RB1 staining or P16 loss showed similar results. The same outcome for chemotherapy treatment was observed in LCNEC tumors harboring an RB1 mutation or lost RB1 protein. Conclusions: Patients with LCNEC tumors that carry a wild-type RB1 gene or express the RB1 protein do better with NSCLC-GEM/TAX treatment than with SCLC-PE chemotherapy. However, no difference was observed for RB1 mutated or with lost protein expression. Clin Cancer Res; 24(1); 33–42. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1921

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 232

Metadata

Authors
Derks, J. L., Leblay, N., Thunnissen, E., van Suylen, R. J., den Bakker, M., Groen, H. J. M., Smit, E. F., Damhuis, R., van den Broek, E. C., Charbrier, A., Foll, M., McKay, J. D., Fernandez-Cuesta, L., Speel, E.-J. M., & Dingemans, A.-M. C.
Venue
Clinical Cancer Research
Published
2018-01-01
Volume
24
Issue
1
Pages
33-42
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2765973383
Cited by
232
References
4
FWCI
6.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1921
The paper
Derks, J. L., Leblay, N., Thunnissen, E., van Suylen, R. J., den Bakker, M., Groen, H. J. M., Smit, E. F., Damhuis, R., van den Broek, E. C., Charbrier, A., Foll, M., McKay, J. D., Fernandez-Cuesta, L., Speel, E.-J. M., & Dingemans, A.-M. C. (2018). Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1921

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.